TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR medicine SNIPR001 into clinical trials in haematological cancer patients April 23, 2024
Edgewood Oncology raises $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors April 2, 2024
Enrollment of 190 Patients to Support Primary Endpoint Analysis in SELECT-MDS-1 Ph 3 Trial completed April 2, 2024
IMBRUVICA® (ibrutinib) Label expanded in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications March 12, 2024
Dosing Initiated in Second Cohort of Ovarian Cancer FSHR-targeting CER-T Clinical Trial February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
IND Applications approved by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors February 26, 2024
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics February 26, 2024
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs February 26, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 31, 2024
Complete Remission Of The Cohort 1 First Patient Treated For R/R B-ALL In Ph 1 Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 31, 2024
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies January 18, 2024
Boehringer Ingelheim And 3T Biosciences Enter Into A Second Partnership To Develop Next-Generation Cancer Immunotherapies January 10, 2024
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases January 10, 2024
Status of Ph 1/2 Study of ONCT-808 in Patients with R/R Aggressive B-cell Lymphoma announced January 10, 2024
